Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze.

BACKGROUND Respiratory syncytial virus (RSV) hospitalization is associated with wheeze. OBJECTIVE To examine the influence of maternally derived RSV neutralizing antibodies in cord blood on RSV hospitalization and recurrent wheeze in infancy. METHODS Among children from the Danish National Birth Cohort, we selected a subcohort of 459 randomly selected children, 408 children with RSV hospitalization, 408 children with recurrent wheeze, and all 289 children who experienced both RSV hospitalization and recurrent wheeze. The influence of cord blood RSV neutralizing antibodies was examined as predictors for (1) RSV hospitalization, (2) RSV hospitalization after recurrent wheeze, (3) recurrent wheeze, and (4) recurrent wheeze after RSV hospitalization. RESULTS Neutralizing antibody levels were inversely associated with RSV hospitalization in infants below 6 months of age (adjusted incidence rate ratio [IRR], 0.74; 95% CI, 0.62-0.87), and also inversely associated with RSV hospitalization in infants with recurrent wheeze (IRR, 0.83; 0.71-0.97). In contrast, neutralizing antibody levels were directly associated with an increased risk of recurrent wheeze in infants below 6 months of age (IRR, 1.28; 1.04-1.57) and with an increased risk of recurrent wheeze after RSV hospitalization in infants below 6 months of age (IRR, 1.44; 1.10-1.90). CONCLUSION Maternally derived RSV neutralizing antibodies protect infants against RSV hospitalization, and also when the infant has recurrent wheeze. However, high maternally derived RSV neutralizing antibody levels were associated with an increased risk of recurrent wheeze.

[1]  E. Arranz,et al.  Similar Cytokine Profiles in Response to Infection with Respiratory Syncytial Virus Type A and Type B in the Upper Respiratory Tract in Infants , 2008, Intervirology.

[2]  N. Anthonisen,et al.  Risk of physician-diagnosed asthma in the first 6 years of life. , 2004, Chest.

[3]  B. Murphy,et al.  Respiratory syncytial virus-specific immunoglobulins in preterm infants. , 1993, The Journal of pediatrics.

[4]  A. Yeager,et al.  Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection. , 1977, American journal of diseases of children.

[5]  H. E. Krause,et al.  Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. , 1976, The Journal of infectious diseases.

[6]  W E Barlow,et al.  Analysis of case-cohort designs. , 1999, Journal of clinical epidemiology.

[7]  A. Frank,et al.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. , 1981, The Journal of pediatrics.

[8]  M. Ogilvie,et al.  Maternal antibody and respiratory syncytial virus infection in infancy , 1981, Journal of medical virology.

[9]  B. Kjellman,et al.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. , 2000, American journal of respiratory and critical care medicine.

[10]  J. Warner,et al.  A hypothesis: antenatal sensitisation to respiratory syncytial virus in viral bronchiolitis , 2002, Archives of Disease in Childhood.

[11]  F. Martinez,et al.  Factors influencing the relation of infant feeding to asthma and recurrent wheeze in childhood , 2001, Thorax.

[12]  W. Morgan,et al.  Asthma and wheezing in the first six years of life. The Group Health Medical Associates. , 1995, The New England journal of medicine.

[13]  J. Devasundaram,et al.  Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus , 2003, The Pediatric infectious disease journal.

[14]  J. Malo,et al.  Family size, day-care attendance, and breastfeeding in relation to the incidence of childhood asthma. , 2001, American journal of epidemiology.

[15]  M. Lebowitz,et al.  Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. , 1991, American journal of epidemiology.

[16]  J. Hierholzer,et al.  Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay , 1985, Journal of clinical microbiology.

[17]  B. Graham,et al.  Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. , 2000, The Journal of infectious diseases.

[18]  M. Ogilvie,et al.  Antibodies to respiratory syncytial virus polypeptides and their significance in human infection. , 1983, The Journal of general virology.

[19]  W. P. Glezen,et al.  Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. , 2003, Vaccine.

[20]  B. Apelberg,et al.  Systematic review: Exposure to pets and risk of asthma and asthma-like symptoms. , 2001, The Journal of allergy and clinical immunology.

[21]  B. Graham,et al.  Respiratory syncytial virus infection prolongs methacholine‐induced airway hyperresponsiveness in ovalbumin‐sensitized mice , 1999, Journal of medical virology.

[22]  P. Aaby,et al.  Diagnosis coding in The Danish National Patient Registry for respiratory syncytial virus infections , 2005, Scandinavian journal of infectious diseases.

[23]  Ayne,et al.  ASTHMA AND WHEEZING IN THE FIRST SIX YEARS OF LIFE , 1995 .

[24]  M. Eriksson,et al.  Wheezing following lower respiratory tract infections with respiratory syncytial virus and influenza A in infancy , 2000, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[25]  B. Graham,et al.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. , 1993, Journal of immunology.

[26]  P. Andersen,et al.  Comparison of case‐cohort estimators based on data on premature death of adult adoptees , 2003, Statistics in medicine.

[27]  C. Hall,et al.  Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .

[28]  P. Aaby,et al.  Thymus size and head circumference at birth and the development of allergic diseases , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  D. Fulton,et al.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children , 1994 .

[30]  Peter Aaby,et al.  Atopic Disposition, Wheezing, and Subsequent Respiratory Syncytial Virus Hospitalization in Danish Children Younger Than 18 Months: A Nested Case-Control Study , 2006, Pediatrics.

[31]  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. , 1998, Pediatrics.

[32]  N. Pearce,et al.  A case‐control study of risk factors for asthma in New Zealand children , 2001, Australian and New Zealand journal of public health.

[33]  W. P. Glezen,et al.  Maternal immunization against viral disease. , 1998, Vaccine.

[34]  K. Mcintosh,et al.  Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study. , 2008, The Journal of allergy and clinical immunology.

[35]  D. Sherrill,et al.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years , 1999, The Lancet.

[36]  T. F. Andersen,et al.  The Danish National Hospital Register. A valuable source of data for modern health sciences. , 1999, Danish medical bulletin.

[37]  L. Anderson,et al.  Day-care center attendance and hospitalization for lower respiratory tract illness. , 1988, Pediatrics.

[38]  E. Simões,et al.  Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. , 2007, The Journal of pediatrics.

[39]  J. Saiz,et al.  Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique , 2002, Journal of medical virology.

[40]  P. Mortensen,et al.  The Danish Civil Registration System. A cohort of eight million persons. , 2006, Danish medical bulletin.

[41]  Henrik Toft Sørensen,et al.  The Danish National Birth Cohort - its background, structure and aim , 2001, Scandinavian journal of public health.

[42]  B. Graham,et al.  Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. , 2000, The Journal of infectious diseases.